Join our daily newsletter At The Bell to receive exclusive market insights
- Creso Pharma’s (CPH) Canadian subsidiary, Mernova medicinal secures new purchase orders in July
- The company have brought in purchase orders worth C$416,340 (A$465,083) last month, representing growth from its June revenue
- CPH says the new orders represent a strong start to the quarter, with purchases for its Ritual Green cannabis strains and Ritual gold vaporiser products driving the growth
- It expects to receive further demand for its products through its Ontario Cannabis store flow-through model, as the North American summer continues
- Shares are trading flat today at 4 cents each at 12:38 pm AEST
Creso Pharma’s (CPH) Canadian subsidiary, Mernova medicinal secured new purchase orders last month.
The company brought in purchase orders worth C$416,340 (A$465,083) in July, representing growth from its June revenue.
CPH said the new orders represent a strong start to the quarter, with purchases for its Ritual Green cannabis strains and Ritual gold vaporiser products driving the growth.
It expects to receive further demand for its products through its Ontario Cannabis store flow-through model, as the North American summer continues.
CEO and Managing Director William Lay said a solid foundation has been laid for further growth during the quarter.
“The company continues to assess opportunities to increase market share across Canada, including the introduction of new strains, products and potential distribution agreements,” he said.
Shares were trading flat today at 4 cents each at 12:38 pm AEST.
